Feature | Stents Bioresorbable | September 04, 2015

Absorbable Stents Prove Non-Inferior to Metal in STEMI Study

Abbott's bioresorbable vascular scaffold performs similarly to gold-standard bare metal stent

ABSORB STEMI TROFI II trial, ESC 2015, bioresorbable vascular scaffold, BVS, STEMI patients

Image courtesy of Abbott Vascular

September 4, 2015 — A drug-eluting coronary stent made of absorbable material performed similarly to gold-standard metal among patients with an ST-segment elevation myocardial infarction (STEMI), according to results of the ABSORB STEMI TROFI II trial.

“This is the first randomized, controlled trial to compare the stent coverage between these two types of stents in the STEMI setting,” said senior investigator Patrick W Serruys, M.D., Ph.D., who presented the findings at the European Society of Cardiology (ESC) Congress 2015, with simultaneous publication in the European Heart Journal.

Unlike metallic stents which remain permanently in place, absorbable stents — also known as “bioresorbable vascular scaffolds” (BVS) — eventually biodegrade, restoring the natural physiology of coronary vessels – “a factor which may be more important in STEMI patients, who tend to have delayed arterial healing as compared to patients with stable coronary artery disease,” explained Serruys, from the International Centre for Circulatory Health, Imperial College, London.

The study included 191 STEMI patients (mean age 58.6 years) undergoing primary percutaneous coronary intervention at eight medical centers.

Patients were randomized to receive either the Abbott Vascular Absorb BVS (n=95) or a metallic stent (n=96), both types being “drug-eluting”, meaning coated in everolimus, a drug to reduce the risk of vessel reblockage.

The primary endpoint of the study was a six-month score assessing stent coverage and restenosis of the vessel using coronary optical coherence tomography (OCT) imaging.

Given the chosen criteria for non-inferiority, the score was similar (1.74 in the BVS arm and 2.80 in the metallic stent arm), indicating almost complete arterial healing in both groups and meeting the criteria for non-inferiority (P<0.001).

Clinical events measured as a composite of cardiac death, target vessel myocardial infarction (MI), or clinically-driven target lesion revascularization, were 1.1 percent in the BVS arm compared to 0 percent in the metallic stent arm (P=ns). There was one case of definite subacute thrombosis in the BVS arm.

“This trial provides the basis for further exploration in clinical outcomes trials,” noted Serruys.

The study was funded by Abbott, the European Cardiovascular Research Institute (ECRI) and Terumo Europe N.V.

Serruys is a member of the international advisory board of Abbott.

For more information: www.escardio.org

Related Content

New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
Overlay Init